ReviewNature reviews. Neurology2019
Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
Review in Nature reviews. Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 298 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
298 citing papers in PubMed, 3 syntheses or guidelines pooled it, 601 citations in OpenAlex.
- Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis.Frontiers in immunology · 2024Pooled it
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.JAMA network open · 2022Pooled it
- Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis.Journal of neurology · 2021Pooled it
- Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.Cell death and differentiation · 2026Review
- Intractable hiccups as a brainstem red flag: demyelinating disorders with emphasis on neuromyelitis optica spectrum disorder and area postrema syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Dynamic characterization of pathological and functional deterioration in a mouse model of optic neuritis related to neuromyelitis optica spectrum disorder.Neural regeneration research · 2026Article
- Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.BMC ophthalmology · 2026Article
- Myelin oligodendrocyte glycoprotein antibody-related autoimmune encephalitis misdiagnosed as acute cerebral infarction: A case report.Medicine · 2026Article
- Article
- Cerebellar Involvement in Immune-Mediated Pediatric Acute Ataxia: Clinical Spectrum, MRI Findings, and Predictors of MOG Antibody Positivity.Cerebellum (London, England) · 2026Article
- Detection of Diagnostic Antibodies in Immune-Mediated Diseases: A Focus on Antigens and Technologies.Chembiochem : a European journal of chemical biology · 2026Review
- Myelin oligodendrocyte glycoprotein antibody-associated disease after transforaminal lumbar interbody fusion surgery: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.Annals of clinical and translational neurology · 2026Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Onset in Pregnancy: A Case Report.Cureus · 2026Article
- Reports of the Clinician's Demise Are Greatly Exaggerated: Clinical Judgment Remains Key in Diagnosing MOGAD.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD.Journal of neurology · 2026Review
- B-Cell Depletion as Evidence for Shared Neuroimmune Pathways in Combined Central and Peripheral Demyelination: A Case Report and Literature Review.International journal of molecular sciences · 2026Review
- Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Acute Disseminated Encephalomyelitis (ADEM): Current View into Etiopathogenesis and Clinical Features.Brain sciences · 2026Review
- A Unique Case of Genetic Creutzfeldt-Jakob Disease (E200K Mutation) with CSF-restricted Anti Myelin Oligodendrocyte Glycoprotein Antibody.Internal medicine (Tokyo, Japan) · 2026Article
238 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG-Abs) were first detected by immunoblot and enzyme-linked immunosorbent assay nearly 30 years ago, but their association with multiple sclerosis (MS) was not specific. Use of cell-based assays with native MOG as the substrate enabled identification of a group of MOG-Ab-positive patients with demyelinating phenotypes. Initially, MOG-Abs were reported in children with acute disseminated encephalomyelitis (ADEM). Further studies identified MOG-Abs in adults and children with ADEM, seizures, encephalitis, anti-aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and related syndromes (optic neuritis, myelitis and brainstem encephalitis), but rarely in MS. This shift in our understanding of the diagnostic assays has re-invigorated the examination of MOG-Abs and their role in autoimmune and demyelinating disorders of the CNS. The clinical phenotypes, disease courses and responses to treatment that are associated with MOG-Abs are currently being defined. MOG-Ab-associated disease is different to AQP4-Ab-positive NMOSD and MS. This Review provides an overview of the current knowledge of MOG, the metrics of MOG-Ab assays and the clinical associations identified. We collate the data on antibody pathogenicity and the mechanisms that are thought to underlie this. We also highlight differences between MOG-Ab-associated disease, NMOSD and MS, and describe our current understanding on how best to treat MOG-Ab-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.